By engineering an antigen-specific single-chain variable-fragment antibody (scFv) fused to intracellular lymphocyte signaling domains, T cells are functionally redirected to specific surface molecules on tumor cells.74 Although CAR T cell therapy for non-hematopoietic solid tumors remains challenging compared to application in B-lineage malignancies, ongoing research and clinical trials include anti-FRα CAR T cells. Here, FOLR1 is linked to neoplasm.